Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Glenmark Pharmaceuticals
Pharmaceutical Preparation ManufacturingIndiaNSE: GLENMARK.NS
Last verified 3 months agoglenmarkpharma.com
Glenmark Pharmaceuticals Limited, commonly referred to as Glenmark Pharma, is a prominent player in the global pharmaceutical preparation manufacturing industry. Headquartered in Mumbai, India, the company has established a significant presence across key markets in Asia, Europe, and the Americas. Founded in 1977, Glenmark has grown steadily, earning recognition for its innovative approach to developing generic medicines, branded formulations, and active pharmaceutical ingredients (APIs).
The company’s core focus lies in delivering high-quality, affordable healthcare solutions, with a strong emphasis on respiratory, dermatology, and oncology segments. Glenmark’s commitment to research and development has led to notable achievements, positioning it as a trusted name in the pharmaceutical sector. Its market reputation is built on a track record of consistent growth, strategic acquisitions, and a dedication to improving patient outcomes worldwide.
49
DitchCarbon score
+7 vs industry average
Glenmark Pharmaceuticals’s score of 49 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Glenmark Pharmaceuticals?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2027
20202021202220232024202520262027
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Glenmark Pharmaceuticals's reported carbon emissions
Glenmark Pharmaceuticals, an Indian pharmaceutical manufacturer, reported total greenhouse gas emissions of approximately 255.2 million kg CO2e in 2024. This included about 15.46 million kg CO2e from Scope 1, 69.63 million kg CO2e from Scope 2, and 171.15 million kg CO2e from Scope 3 emissions.
In 2023, the company's total emissions were approximately 252.58 million kg CO2e, comprising about 12.7 million kg CO2e (Scope 1), 64.81 million kg CO2e (Scope 2), and 175.07 million kg CO2e (Scope 3). Looking further back, in 2022, Glenmark Pharmaceuticals's total emissions were around 201.13 million kg CO2e (14.97 million kg CO2e Scope 1, 66.74 million kg CO2e Scope 2, and 119.43 million kg CO2e Scope 3).
Glenmark Pharmaceuticals has set ambitious climate commitments. The company aims for carbon neutrality by 2030, covering both Scope 1 and Scope 2 emissions, as well as an overall carbon neutrality target for all scopes by 2030. These targets are supported by Science Based Targets initiative (SBTi) commitments. Glenmark Pharmaceuticals Limited commits to reduce absolute Scope 1 and 2 GHG emissions by 35% by FY2035 from a FY2021 base year. Additionally, the company is committed to reducing Scope 3 GHG emissions from purchased goods and services, fuel and energy-related activities, downstream transportation and distribution, and investments by 28% per tonne of pharmaceutical products within the same timeframe. These SBTi targets for Scope 1 and 2 emissions are classified as consistent with reductions required to keep warming to "Well-below 2°C".
Assessing Glenmark Pharmaceuticals as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Glenmark Pharmaceuticals and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Glenmark Pharmaceuticals’s Climate Goals (2030 & 2050)
3 goals2035
35% reduction in Scope 1
Glenmark Pharmaceuticals Limited commits to reduce absolute scope 1 and 2 GHG emissions 35% by FY2035 from a FY2021 base year.* Glenmark Pha…
Behind target35%
2035
35% reduction in Scope 2
Glenmark Pharmaceuticals Limited commits to reduce absolute scope 1 and 2 GHG emissions 35% by FY2035 from a FY2021 base year.* Glenmark Pha…
Behind target35%
2035
28% reduction in scope 3 downstream
Insufficient data28%
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
FY2035 targetSee details
Active
Carbon Disclosure Project
Sign in to view
Active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Glenmark Pharmaceuticals3 months ago
49
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Frequently asked questions
Common questions about Glenmark Pharmaceuticals’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more